ASK REDCHAT ANYTHING ABOUT BIOLINERX LTD.
BioLineRx Ltd. (NASDAQ: BLRX)
Listen to this Section
$3.18
+0.0610
(
+1.96% )
3.4K
Sign up for The Small Stocks Big Money Newsletter and receive free small-cap news and insights.
Clinical Trial Pipeline Stages
| Drug Name |
Stage |
| APHEXDA®(Motixafortide )(BL-8040) (CXCR4 antagonist)DetailsStem cell mobilization, Multiple myeloma |
Approved |
| Motixafortide (BL-8040) w/ zimberelimabDetailsPancreatic cancer, Cancer, Solid tumor/s |
Phase 2b |
| Motixafortide (BL-8040) w/ cemiplimabDetailsCancer, Solid tumor/s, Pancreatic cancer |
Phase 2 |
| Motixafortide (BL-8040)DetailsBlood disorder, Sickle cell disease |
Phase 1 |
| Motixafortide (BL-8040) +/- natalizumabDetailsSickle cell disease, Blood disorder |
Phase 1 |
| AGI-134DetailsSolid tumor/s, Cancer |
Failed |
| Motixafortide (BL-8040) (CXCR4 antagonist)DetailsAcute myeloid leukemia |
Failed |
| Motixafortide (BL-8040) (CXCR4 antagonist)DetailsPancreatic cancer, Solid tumor/s, Cancer |
Failed |
Market Data
|
| Open |
$3.18 |
| Previous Close |
$3.12 |
| Volume |
3.4K |
| Market Cap |
$14.66M |
| Day Range |
$3.07 - $3.46 |
| 52 Week Range |
$2.15 - $5.06 |
| Shares Outstanding |
4.35M |
| Change % |
+1.96% |
| Net Change |
▲ 0.0610 |
| Insider Ownership |
N/A |
| Exchange |
NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations |
| IPO Year | 2011 |
| Country | Israel |
Insider Ownership Transactions
Total Amount Purchased:
0.00
| Date |
Type |
Amount Purchased |
Purchaser |
| No records found. |
SEC Filings
| Form Type |
Description |
Pages |
Date |
| 3 |
Insider transactions |
1 |
Mar 31, 2026 |
| 3 |
Insider transactions |
1 |
Mar 31, 2026 |
| 3 |
Insider transactions |
1 |
Mar 31, 2026 |
| 3 |
Insider transactions |
1 |
Mar 31, 2026 |
| 3 |
Insider transactions |
1 |
Mar 30, 2026 |
| 3 |
Insider transactions |
1 |
Mar 30, 2026 |
| 3 |
Insider transactions |
1 |
Mar 27, 2026 |
| 6-k |
Form 6-K |
5 |
Mar 26, 2026 |
| 6-k |
Form 6-K |
4 |
Mar 23, 2026 |
| 3 |
Insider transactions |
1 |
Mar 18, 2026 |